Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

The role of occult hypertension in retinal vein occlusions and diabetic retinopathy.

Pesin N, Mandelcorn ED, Felfeli T, Ogilvie RI, Brent MH.

Can J Ophthalmol. 2017 Nov;52 Suppl 1:S30-S33. doi: 10.1016/j.jcjo.2017.09.024.

PMID:
29074010
2.

The role of occult hypertension in retinal vein occlusions and diabetic retinopathy.

Pesin N, Mandelcorn ED, Felfeli T, Ogilvie RI, Brent MH.

Can J Ophthalmol. 2017 Apr;52(2):225-228. doi: 10.1016/j.jcjo.2016.09.009. Epub 2017 Jan 9.

PMID:
28457296
3.

Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension.

Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GV, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Hiremath S, Drouin D, Lavoie KL, Hamet P, Fodor G, Grégoire JC, Lewanczuk R, Dresser GK, Sharma M, Reid D, Lear SA, Moullec G, Gupta M, Magee LA, Logan AG, Harris KC, Dionne J, Fournier A, Benoit G, Feber J, Poirier L, Padwal RS, Rabi DM; CHEP Guidelines Task Force.

Can J Cardiol. 2016 May;32(5):569-88. doi: 10.1016/j.cjca.2016.02.066. Epub 2016 Mar 10.

PMID:
27118291
4.

The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Daskalopoulou SS, Rabi DM, Zarnke KB, Dasgupta K, Nerenberg K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, McKay DW, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Ramesh Prasad GV, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Brian Penner S, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Hiremath S, Stone JA, Drouin D, Lavoie KL, Hamet P, Fodor G, Grégoire JC, Fournier A, Lewanczuk R, Dresser GK, Sharma M, Reid D, Benoit G, Feber J, Harris KC, Poirier L, Padwal RS.

Can J Cardiol. 2015 May;31(5):549-68. doi: 10.1016/j.cjca.2015.02.016. Review.

PMID:
25936483
5.

The 2014 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Dasgupta K, Quinn RR, Zarnke KB, Rabi DM, Ravani P, Daskalopoulou SS, Rabkin SW, Trudeau L, Feldman RD, Cloutier L, Prebtani A, Herman RJ, Bacon SL, Gilbert RE, Ruzicka M, McKay DW, Campbell TS, Grover S, Honos G, Schiffrin EL, Bolli P, Wilson TW, Lindsay P, Hill MD, Coutts SB, Gubitz G, Gelfer M, Vallée M, Prasad GV, Lebel M, McLean D, Arnold JM, Moe GW, Howlett JG, Boulanger JM, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Burns KD, Petrella RJ, Hiremath S, Milot A, Stone JA, Drouin D, Lavoie KL, Lamarre-Cliche M, Tremblay G, Hamet P, Fodor G, Carruthers SG, Pylypchuk GB, Burgess E, Lewanczuk R, Dresser GK, Penner SB, Hegele RA, McFarlane PA, Khara M, Pipe A, Oh P, Selby P, Sharma M, Reid DJ, Tobe SW, Padwal RS, Poirier L; Canadian Hypertension Education Program.

Can J Cardiol. 2014 May;30(5):485-501. doi: 10.1016/j.cjca.2014.02.002. Epub 2014 Feb 22. Review.

6.

The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.

Hackam DG, Quinn RR, Ravani P, Rabi DM, Dasgupta K, Daskalopoulou SS, Khan NA, Herman RJ, Bacon SL, Cloutier L, Dawes M, Rabkin SW, Gilbert RE, Ruzicka M, McKay DW, Campbell TS, Grover S, Honos G, Schiffrin EL, Bolli P, Wilson TW, Feldman RD, Lindsay P, Hill MD, Gelfer M, Burns KD, Vallée M, Prasad GV, Lebel M, McLean D, Arnold JM, Moe GW, Howlett JG, Boulanger JM, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Milot A, Stone JA, Drouin D, Lavoie KL, Lamarre-Cliche M, Godwin M, Tremblay G, Hamet P, Fodor G, Carruthers SG, Pylypchuk GB, Burgess E, Lewanczuk R, Dresser GK, Penner SB, Hegele RA, McFarlane PA, Sharma M, Reid DJ, Tobe SW, Poirier L, Padwal RS; Canadian Hypertension Education Program.

Can J Cardiol. 2013 May;29(5):528-42. doi: 10.1016/j.cjca.2013.01.005. Epub 2013 Mar 29.

PMID:
23541660
7.

The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.

Daskalopoulou SS, Khan NA, Quinn RR, Ruzicka M, McKay DW, Hackam DG, Rabkin SW, Rabi DM, Gilbert RE, Padwal RS, Dawes M, Touyz RM, Campbell TS, Cloutier L, Grover S, Honos G, Herman RJ, Schiffrin EL, Bolli P, Wilson T, Feldman RD, Lindsay MP, Hemmelgarn BR, Hill MD, Gelfer M, Burns KD, Vallée M, Prasad GV, Lebel M, McLean D, Arnold JM, Moe GW, Howlett JG, Boulanger JM, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Bacon SL, Petrella RJ, Milot A, Stone JA, Drouin D, Lamarre-Cliché M, Godwin M, Tremblay G, Hamet P, Fodor G, Carruthers SG, Pylypchuk G, Burgess E, Lewanczuk R, Dresser GK, Penner B, Hegele RA, McFarlane PA, Sharma M, Campbell NR, Reid D, Poirier L, Tobe SW; Canadian Hypertension Education Program.

Can J Cardiol. 2012 May;28(3):270-87. doi: 10.1016/j.cjca.2012.02.018. Review.

PMID:
22595447
8.

Invited Lecture - CSPT Annual Meeting: Drugs and people I have known: 45 years in clinical pharmacology.

Ogilvie RI.

J Popul Ther Clin Pharmacol. 2011;18(3):e455-70. Epub 2011 Sep 12.

PMID:
21994413
9.

The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy.

Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, Myers MG, McKay DW, Quinn RR, Hemmelgarn BR, Cloutier L, Bolli P, Hill MD, Wilson T, Penner B, Burgess E, Lamarre-Cliché M, McLean D, Schiffrin EL, Honos G, Mann K, Tremblay G, Milot A, Chockalingam A, Rabkin SW, Dawes M, Touyz RM, Burns KD, Ruzicka M, Campbell NR, Vallée M, Prasad GV, Lebel M, Campbell TS, Lindsay MP, Herman RJ, Larochelle P, Feldman RD, Arnold JM, Moe GW, Howlett JG, Trudeau L, Bacon SL, Petrella RJ, Lewanczuk R, Stone JA, Drouin D, Boulanger JM, Sharma M, Hamet P, Fodor G, Dresser GK, Carruthers SG, Pylypchuk G, Gilbert RE, Leiter LA, Jones C, Ogilvie RI, Woo V, McFarlane PA, Hegele RA, Poirier L, Tobe SW; Canadian Hypertension Education Program.

Can J Cardiol. 2011 Jul-Aug;27(4):415-433.e1-2. doi: 10.1016/j.cjca.2011.03.015. English, French.

PMID:
21801975
10.

The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.

Hackam DG, Khan NA, Hemmelgarn BR, Rabkin SW, Touyz RM, Campbell NR, Padwal R, Campbell TS, Lindsay MP, Hill MD, Quinn RR, Mahon JL, Herman RJ, Schiffrin EL, Ruzicka M, Larochelle P, Feldman RD, Lebel M, Poirier L, Arnold JM, Moe GW, Howlett JG, Trudeau L, Bacon SL, Petrella RJ, Milot A, Stone JA, Drouin D, Boulanger JM, Sharma M, Hamet P, Fodor G, Dresser GK, Carruthers SG, Pylypchuk G, Burgess ED, Burns KD, Vallée M, Prasad GV, Gilbert RE, Leiter LA, Jones C, Ogilvie RI, Woo V, McFarlane PA, Hegele RA, Tobe SW; Canadian Hypertension Education Program.

Can J Cardiol. 2010 May;26(5):249-58. Review.

11.

The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy.

Khan NA, Hemmelgarn B, Herman RJ, Bell CM, Mahon JL, Leiter LA, Rabkin SW, Hill MD, Padwal R, Touyz RM, Larochelle P, Feldman RD, Schiffrin EL, Campbell NR, Moe G, Prasad R, Arnold MO, Campbell TS, Milot A, Stone JA, Jones C, Ogilvie RI, Hamet P, Fodor G, Carruthers G, Burns KD, Ruzicka M, DeChamplain J, Pylypchuk G, Petrella R, Boulanger JM, Trudeau L, Hegele RA, Woo V, McFarlane P, Vallée M, Howlett J, Bacon SL, Lindsay P, Gilbert RE, Lewanczuk RZ, Tobe S; Canadian Hypertension Education Program.

Can J Cardiol. 2009 May;25(5):287-98. Review.

12.
13.

The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.

Khan NA, Hemmelgarn B, Herman RJ, Rabkin SW, McAlister FA, Bell CM, Touyz RM, Padwal R, Leiter LA, Mahon JL, Hill MD, Larochelle P, Feldman RD, Schiffrin EL, Campbell NR, Arnold MO, Moe G, Campbell TS, Milot A, Stone JA, Jones C, Ogilvie RI, Hamet P, Fodor G, Carruthers G, Burns KD, Ruzicka M, dechamplain J, Pylypchuk G, Petrella R, Boulanger JM, Trudeau L, Hegele RA, Woo V, McFarlane P, Vallée M, Howlett J, Katzmarzyk P, Tobe S, Lewanczuk RZ; Canadian Hypertension Education Program.

Can J Cardiol. 2008 Jun;24(6):465-75. Review.

14.

Aortic diameter, wall stiffness, and wave reflection in systolic hypertension.

Mitchell GF, Conlin PR, Dunlap ME, Lacourcière Y, Arnold JM, Ogilvie RI, Neutel J, Izzo JL Jr, Pfeffer MA.

Hypertension. 2008 Jan;51(1):105-11. Epub 2007 Dec 10.

PMID:
18071054
15.

The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.

Khan NA, Hemmelgarn B, Padwal R, Larochelle P, Mahon JL, Lewanczuk RZ, McAlister FA, Rabkin SW, Hill MD, Feldman RD, Schiffrin EL, Campbell NR, Logan AG, Arnold M, Moe G, Campbell TS, Milot A, Stone JA, Jones C, Leiter LA, Ogilvie RI, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, Burns KD, Ruzicka M, deChamplain J, Pylypchuk G, Gledhill N, Petrella R, Boulanger JM, Trudeau L, Hegele RA, Woo V, McFarlane P, Touyz RM, Tobe SW; Canadian Hypertension Education Program.

Can J Cardiol. 2007 May 15;23(7):539-50.

16.

The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy.

Khan NA, McAlister FA, Rabkin SW, Padwal R, Feldman RD, Campbell NR, Leiter LA, Lewanczuk RZ, Schiffrin EL, Hill MD, Arnold M, Moe G, Campbell TS, Herbert C, Milot A, Stone JA, Burgess E, Hemmelgarn B, Jones C, Larochelle P, Ogilvie RI, Houlden R, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, Dechamplain J, Pylypchuk G, Logan AG, Gledhill N, Petrella R, Tobe S, Touyz RM; Canadian Hypertension Education Program.

Can J Cardiol. 2006 May 15;22(7):583-93.

17.

The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.

Khan NA, McAlister FA, Lewanczuk RZ, Touyz RM, Padwal R, Rabkin SW, Leiter LA, Lebel M, Herbert C, Schiffrin EL, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, DeChamplain J, Pylypchuk G, Logan AG, Gledhill N, Petrella R, Campbell NR, Arnold M, Moe G, Hill MD, Jones C, Larochelle P, Ogilvie RI, Tobe S, Houlden R, Burgess E, Feldman RD; Canadian Hypertension Education Program.

Can J Cardiol. 2005 Jun;21(8):657-72.

PMID:
16003449
18.

Adverse events: past and future.

Ruedy J, Ogilvie RI.

CMAJ. 2004 Sep 14;171(6):549; author reply 550, 552. No abstract available.

19.

The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy.

McAlister FA, Zarnke KB, Campbell NR, Feldman RD, Levine M, Mahon J, Grover SA, Lewanczuk R, Leenen F, Tobe S, Lebel M, Stone J, Schiffrin EL, Rabkin SW, Ogilvie RI, Larochelle P, Jones C, Honos G, Fodor G, Burgess E, Hamet P, Herman R, Irvine J, Culleton B, Wright JM; Canadian Hypertension Recommendations Working Group.

Can J Cardiol. 2002 Jun;18(6):625-41.

PMID:
12107420
20.

The death of a volunteer research subject: lessons to be learned.

Ogilvie RI.

CMAJ. 2001 Nov 13;165(10):1335-7. No abstract available.

21.

High-altitude illness.

Ogilvie RI.

N Engl J Med. 2001 Oct 25;345(17):1279-80; author reply 1280-1. No abstract available.

PMID:
11680461
23.

Captopril and angiotensin II receptor antagonist therapy in a pacing model of heart failure.

Ogilvie RI, Zborowska-Sluis D.

Can J Cardiol. 1998 Aug;14(8):1025-33. Review.

PMID:
9738162
24.

Isolated systolic hypertension in the elderly--what's next?

Ogilvie RI.

Geriatr Nephrol Urol. 1998;8(1):3-5. No abstract available.

PMID:
9650040
25.

Recommendations for sick-leave from work for patients with hypertension. Canadian Hypertension Society.

Ogilvie RI, Ellis E, Langlois S, MacKenzie R, Spence JD.

Can J Cardiol. 1996 Jan;12(1):31-2. No abstract available.

PMID:
8595566
26.

Vascular capacitance and cardiac output in pacing-induced canine models of acute and chronic heart failure.

Ogilvie RI, Zborowska-Sluis D.

Can J Physiol Pharmacol. 1995 Nov;73(11):1641-50.

PMID:
8789419
27.

Effect of perindopril in pacing-induced canine models of acute and chronic heart failure.

Ogilvie RI, Zborowska-Sluis D.

Can J Cardiol. 1995 Nov;11(10):934-40.

PMID:
7489534
28.

Acute effect of L-arginine on hemodynamics and vascular capacitance in the canine pacing model of heart failure.

Ogilvie RI, Zborowska-Sluis D.

J Cardiovasc Pharmacol. 1995 Sep;26(3):407-13.

PMID:
8583782
29.

Acute hemodynamic effects of drugs acting on the renin-angiotensin system in acute heart failure.

Nekooeian AA, Ogilvie RI, Zborowska-Sluis D.

Can J Cardiol. 1995 Jan;11(1):59-64.

PMID:
7850666
30.

Effect of captopril treatment on total and central vascular capacitance in dogs with chronic heart failure.

Ogilvie RI, Zborowska-Sluis D.

J Cardiovasc Pharmacol. 1994 Sep;24(3):358-64.

PMID:
7528290
31.

Pharmacokinetic and pharmacodynamic interactions during multiple-dose administration of nisoldipine and propranolol.

Shaw-Stiffel TA, Walker SE, Ogilvie RI, Leenen FH.

Clin Pharmacol Ther. 1994 Jun;55(6):661-9.

PMID:
8004882
32.

Report of the Canadian Hypertension Society Consensus Conference: 3. Pharmacologic treatment of essential hypertension.

Ogilvie RI, Burgess ED, Cusson JR, Feldman RD, Leiter LA, Myers MG.

CMAJ. 1993 Sep 1;149(5):575-84. Review. No abstract available.

33.

Captopril attenuates pacing-induced acute heart failure by increasing total vascular capacitance.

Ogilvie RI, Zborowska-Sluis D.

J Cardiovasc Pharmacol. 1993 Jul;22(1):153-9.

PMID:
7690088
34.

Calcium antagonists in heart transplant recipients: effects on cardiac and renal function and cyclosporine pharmacokinetics.

Legault L, Ogilvie RI, Cardella CJ, Leenen FH.

Can J Cardiol. 1993 Jun;9(5):398-404.

PMID:
8348391
35.

Acute effect of rapid ventricular pacing and volume loading on total vascular capacitance.

Ogilvie RI, Zborowska-Sluis D.

Can J Cardiol. 1992 Dec;8(10):1071-8.

PMID:
1288839
36.

Effect of chronic rapid ventricular pacing on total vascular capacitance.

Ogilvie RI, Zborowska-Sluis D.

Circulation. 1992 Apr;85(4):1524-30.

PMID:
1555292
37.

Isoproterenol increases defibrillation energy requirements in dogs.

Wang M, Dorian P, Ogilvie RI.

J Cardiovasc Pharmacol. 1992 Feb;19(2):201-8.

PMID:
1376789
38.
39.

Effects of nitroglycerin and nitroprusside on vascular capacitance of anesthetized ganglion-blocked dogs.

Ogilvie RI, Zborowska-Sluis D.

J Cardiovasc Pharmacol. 1991 Oct;18(4):574-80.

PMID:
1724535
40.

A Canadian multicentre study of a 48 h infusion of milrinone in patients with severe heart failure.

Pflugfelder PW, O'Neill BJ, Ogilvie RI, Beanlands DS, Tanser PH, Tihal H, Mizgala HF, Fitchett DH, Kostuk WJ.

Can J Cardiol. 1991 Jan-Feb;7(1):5-10.

PMID:
2025794
41.

Measurement of mean circulatory filling pressure and vascular compliance in domestic pigs.

Ogilvie RI, Zborowska-Sluis D, Tenaschuk B.

Am J Physiol. 1990 Jun;258(6 Pt 2):H1925-32.

PMID:
2360680
42.

Effects of nifedipine and captopril on vascular capacitance of ganglion-blocked anesthetized dogs.

Ogilvie RI, Zborowska-Sluis D.

Can J Physiol Pharmacol. 1990 Mar;68(3):431-8.

PMID:
1969766
43.

Short-term effects of calcium antagonists on hemodynamics and cyclosporine pharmacokinetics in heart-transplant and kidney-transplant patients.

Roy LF, East DS, Browning FM, Shaw D, Ogilvie RI, Cardella C, Leenen FH.

Clin Pharmacol Ther. 1989 Dec;46(6):657-67.

PMID:
2689045
44.

Cardiac and vascular effects of atrial natriuretic factor and sodium nitroprusside in healthy men.

Roy LF, Ogilvie RI, Larochelle P, Hamet P, Leenen FH.

Circulation. 1989 Feb;79(2):383-92.

PMID:
2536599
45.

Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol.

Levine MA, Ogilvie RI, Leenen FH.

Clin Pharmacol Ther. 1988 Jan;43(1):39-48.

PMID:
2826066
46.

Persistence of the electrophysiologic effects of mexiletine in canine Purkinje fibers alters the response to subsequent hypoxia.

Berman ND, Ogilvie RI, Loukides JE.

Can J Physiol Pharmacol. 1987 Oct;65(10):2104-9.

PMID:
3427544
47.

Compartmental vascular changes in dogs after nephrectomy, DOCA, and saline: effect of nifedipine.

Ogilvie RI, Zborowska-Sluis D.

Can J Physiol Pharmacol. 1987 Sep;65(9):1891-7.

PMID:
3690408
48.

Analysis of venous flow transients for estimation of vascular resistance, compliance, and blood flow distribution.

Ogilvie RI, Zborowska-Sluis D.

Can J Physiol Pharmacol. 1987 Sep;65(9):1884-90.

PMID:
3690407
49.

Pharmacokinetic disposition of isoxicam in hepatic cirrhosis.

Esquivel M, Ogilvie RI, East DS, Shaw DH Jr, Heathcote J.

Clin Invest Med. 1987 Sep;10(5):363-7.

PMID:
3677504
50.

The clinical pharmacology section of the International Union of Pharmacology.

Ogilvie RI.

Clin Pharmacol Ther. 1987 Apr;41(4):365-7. No abstract available.

PMID:
3829574

Supplemental Content

Loading ...
Support Center